Advertisement

Pravastatin prevents the progression of accelerated coronary artery disease after heart transplantation in a rabbit model

  • N. Ogawa
  • I. Koyama
  • T. Shibata
  • T. Watanabe
  • N. Akimoto
  • Y. Taguchi
  • N. Shinozuka
  • R. Omoto
Conference paper

Abstract

This study was designed to investigate the effects of pravastatin (Pr) on accelerated coronary arteriosclerosis in transplanted hearts. The rabbit hearts were transplanted to the recipients’ neck heterotopically, and received FK506. The rabbits in group 1 were fed a normal diet (ND), and cholesterol-rich diet (CD) in group 2 and 3. Pr (10 mg/kg) was given to group 3. They were sacrificed at 4 weeks and the severity of myocardial rejection and arteriosclerosis was assessed and scored histologically. The serum lipid levels were significantly elevated by a CD. However, addition of Pr had no effect on the levels of LDL and total cholesterol (TC). There was no significant difference in myocardial rejection in each group. Transplanted hearts in group 2 showed more severe arteriosclerotic lesions than those in group 1. Pr treatment in group 3 diminished the severity of coronary arteriosclerosis. Pr may prevent the accelerated coronary arteriosclerosis after heart transplantation without significant changes in TC and LDL.

Key words

Heart transplantation Coronary arteriosclerosis Pravastatin FK506 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alonso DR, Starek PF, Minick CR (1977) Studies on pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by synergy of graft rejection and hypercholesterolemia. Am J Pathol 87: 415–422PubMedGoogle Scholar
  2. 2.
    Billingham ME (1987) Cardiac transplant atherosclerosis. Transplant Proc 19: 19–25PubMedGoogle Scholar
  3. 3.
    Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 9: 587–593PubMedGoogle Scholar
  4. 4.
    Carrel A (1907) The surgery of blood vessels, etc. Bull Johns Hobkins Hosp 18: 18Google Scholar
  5. 5.
    Corsini A, Rainteri M, Soma MR, Gabbiani G, Paoletti R (1992) Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 25: 399–400PubMedCrossRefGoogle Scholar
  6. 6.
    Eich D, Thompson JA, Ko D, Hatillo A, 10. Lower R, Katz S, Katz M, Hess ML (1991) Hypercholesterolemia in long term survivors of heart transplantation. An early marker of accelerated coronary artery disease. J Heart Lung Transplant 10: 45–49Google Scholar
  7. 7.
    Gao SZ, Schroeder JS, Alderman EL, 11. Hunt SA, Silverman JF, Wiederhold V, Stinson EB (1987) Clinical laboratory correlates of accelerated coronary ar- 12. tery disease in the cardiac transplant patient. Circulation 76: 56–61Google Scholar
  8. 8.
    Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer Pe, Stinson EB, Shumway NE (1989) Cytomegalovirus infection is 13. associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 261: 3561–3566CrossRefGoogle Scholar
  9. 9.
    Hidaka Y, Eda T, Yonemoto M, Kamei T (1992) Inhibition of cultured vascular smooth muscle cell migration by sim- 14. vastatin (MK-733). Atherosclerosis 95: 87–94PubMedCrossRefGoogle Scholar
  10. 10.
    Meiser BM, Wenke K, Thiery J, Wolf S, Devens Ch, Seidel D, Hammer C, Bellingham ME, Reichart B (1993) Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 25: 2077–2079PubMedGoogle Scholar
  11. 11.
    Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Science 362: 801–809Google Scholar
  12. 12.
    Sarris GE, Mitchell RS, Gillingham ME, Glasson JR, Cahill PD, Miller DC (1989) Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil. J Thorac Cardiovasc Surg 97: 841–855PubMedGoogle Scholar
  13. 13.
    Shibata T, Ogawa N, Koyama I, Kaneko N, Hokazono K, Omoto R (1993) FK506 accelerates the development of coronary artery disease in the transplanted heart as well as the native heart? Transplant Proc 25: 1145–1148PubMedGoogle Scholar
  14. 14.
    Soma MR, Dometti E, Parolini C, Ferrari G, Fumagalli R, Paoletti R (1993) HMG COA reductase inhibitors — In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb 13: 266–273CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • N. Ogawa
    • 1
  • I. Koyama
    • 1
  • T. Shibata
    • 1
  • T. Watanabe
    • 1
  • N. Akimoto
    • 1
  • Y. Taguchi
    • 1
  • N. Shinozuka
    • 1
  • R. Omoto
    • 1
  1. 1.Department of SurgerySaitama Medical SchoolMoroyama-machi, Iruma-gun, SaitamaJapan

Personalised recommendations